| Accession |
PRJCA011537 |
| Title |
CheckMate 649: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 649 |
| Relevance |
Medical |
| Data types |
Clinical, Image, Biomaker (PD-L1) and Metabolic
|
| Organisms |
Homo sapiens
|
| Description |
A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer |
| Sample scope |
Multiisolate |
| Release date |
2022-08-30 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Bristol-Myers Squibb (China) Investment Co., Ltd., Bristol-Myers Squibb Company
|
|
2017L01513
|
|
|
|
| Submitter |
lin
shen (linshenpku@163.com)
|
| Organization |
Beijing Cancer Hospital |
| Submission date |
2022-08-30 |
